Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMIT Melanoma: Nivolumab and Hydroxychloroquine +/- Ipilimumab in Advanced Melanoma
NCT04464759Phase 2Active, not recruiting
- Start
- Oct 2020
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine in melanoma. Started Oct 2020; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04464759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464759.